# Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene

> **NCT03448081** · PHASE2 · COMPLETED · sponsor: **Sienna Biopharmaceuticals** · enrollment: 73 (actual)

## Conditions studied

- Pruritus
- Psoriasis

## Interventions

- **DRUG:** SNA-120
- **DRUG:** Placebo
- **DRUG:** Calcipotriene

## Key facts

- **NCT ID:** NCT03448081
- **Lead sponsor:** Sienna Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-12
- **Primary completion:** 2018-11-21
- **Final completion:** 2018-12-10
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2019-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03448081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03448081, "Safety, Tolerability and Efficacy of SNA-120 for Treatment of Pruritus and Psoriasis in Subjects Treated With Calcipotriene". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03448081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*